Feature | November 08, 2012

FDA Develops Regulations for Intra-aortic Balloon Pumps 40 Years After Their Introduction

Panel will also discuss other cardiovascular technologies grandfathered after tightened restrictions implemented in 1979

FDA Intra-Aortic Balloon Pumps

November 8, 2012 — A U.S. Food and Drug Administration (FDA) advisory committee is meeting Dec. 5 to discuss how to classify and regulate intra-aortic balloon pumps (IABPs), which have been grandfathered without clear policy since the FDA tightened regulations on medical devices in the late 1970s. The panel will also discuss classifications for two other grandfathered technologies, including external counter-pulsating (ECP) devices and cardiopulmonary bypass blood pumps.

The meeting will be held Dec. 5 and 6 from 8 a.m. to 6 p.m. at the Holiday Inn, Gaithersburg, Md.

On Dec. 5, the Circulatory System Devices Panel of the Medical Devices Advisory Committee will discuss making recommendations regarding regulatory classification of IABPs to either reconfirm to class III (subject to premarket approval application [PMA]) or reclassify to class I or class II (subject to premarket notification [510(k)]). IABPs and their control systems are one of the remaining pre-amendment class III devices.

In 1979, the FDA published a proposed rule for classification of IABP devices as class III requiring PMA. The panel recommended class III because the device is life supporting and because the panel believed that insufficient medical and scientific information existed to establish a standard to assure the safety and effectiveness of the device. The panel also stated that controversy exists as to whether the device is beneficial in the many situations in which it is used, and that it is difficult to use the device safely and effectively.

Subsequent to the proposed rule, in 1980, the FDA classified IABP devices into class III after receiving no comments on the proposed rule. In 1987, FDA published a clarification by inserting language in the codified language, stating that no effective date had been established for the requirement for premarket approval for IABP devices.

On Dec. 5, the committee will also discuss external counter-pulsating (ECP) devices. These systems typically consist of a treatment table, pressure cuffs and a controller. They are intended to provide noninvasive circulatory support by applying external pressure to the lower extremities during diastole to increase coronary perfusion pressure, and releasing external pressure during systole to reduce left ventricular workload.  

On Dec. 6, the committee will discuss nonroller-type cardiopulmonary bypass blood pumps, another remaining pre-amendment class III device. These devices use a method other than revolving rollers to pump blood. The FDA has reviewed two types: Centrifugal type pumps utilize a rotor to impart energy to the blood in an extracorporeal circuit through centrifugal forces. These pumps are part of an extracorporeal circuit usually containing an oxygenator and are intended to provide cardiopulmonary support, during procedures such as cardiopulmonary bypass surgery, for periods lasting six hours or less. Micro-axial type pumps are comprised of a pump motor, a cannula and a catheter that connects to a console. These pumps are not designed to be used with an oxygenator but are temporarily placed within the heart or vasculature to provide cardiac support only.    

FDA intends to make background material available to the public no later than two business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's website after the meeting.

For more information: www.fda.gov/AdvisoryCommittees/default.htm

Related Content

Edwards Intuity aortic valve, surgical aortic valve replacement, PinnacleHealth, first U.S. implants
News | Heart Valve Technology| August 26, 2016
This week, PinnacleHealth, Harrisburg, Pa., became the first hospital in the country to implant the Edwards Intuity...

MRI brain scan of a 26-day-old neonate with Zika virus. It shows septation in the ventricle at the arrow. See more Zika radiology images at http://pubs.rsna.org/doi/full/10.1148/radiol.2016161584.

 

News | Cardiovascular Surgery| August 26, 2016
August 26, 2016 — As a further safety measure against the emerging Zika virus outbreak, the U.S.
cardiac surgery, simulation training, University of Washington, case studies

Multiple repetitions of bypass grafts on a heart, using the Ramphal simulator. Courtesy of the University of Washington in Seattle.

News | Cardiovascular Surgery| August 25, 2016
August 25, 2016 — Simulation training fo
Intact Vascular, TOBA clinical study, one-year results, Tack Endovascular System, Journal of Vascular Surgery
News | Peripheral Arterial Disease (PAD)| August 24, 2016
Intact Vascular Inc. announced that the one-year results from its Tack Optimized Balloon Angioplasty (TOBA) clinical...
Technavio report, renal denervation devices, 2015
News | Renal Denervation| August 23, 2016
August 23, 2016 — Technavio analysts forecast the global...
Jason Burdick, injectable hydrogels, heart failure, heart attack, American Chemical Society

Compared to other types of hydrogels being developed (left), a new hydrogel (right) can form crosslinks after injection into the heart, making the material stiffer and longer-lasting. Image courtesy of American Chemical Society.

News | Heart Failure| August 23, 2016
August 23, 2016 — During a heart attack, clots or narrowed arteries block blood flow, harming or killing cells within
News | Peripheral Arterial Disease (PAD)| August 22, 2016
Avinger Inc. recently announced the closing of its previously announced public offering of 9,857,800 shares of Avinger’...
DMC Heart Hospital, Detroit Medical Center, complex percutaneous intervention education course, PCI, cath lab training
News | Cath Lab| August 22, 2016
The Detroit Medical Center (DMC) Heart Hospital recently completed a Complex Percutaneous Intervention education course...
TAILOR-PCI study, antiplatelet medication, genotype, NHLBI grant
News | Antiplatelet and Anticoagulation Therapies| August 18, 2016
Researchers at the Peter Munk Cardiac Centre, Toronto, and at Mayo Clinic are leading the Tailored Antiplatelet Therapy...
Covidien, Medtronic, TurboHawk, Atherectomy system

The Medtronic TurboHawk atherectomy system. 

Feature | Atherectomy Devices| August 18, 2016 | Dave Fornell
Due to poor outcomes from percutaneous transluminal angioplasty (PTA) ballooning of vessels alone, or of stenting in
Overlay Init